BioSig and Mayo Clinic Collaborate on New R&D Program to Develop Transformative AI and Machine Learning Technologies for its PURE EP™ System

byNASDAQ Market NewsFebruary 2, 2021

NASDAQ Market News
Click here to email author

NeurMedix Obtains FDA Authorization for Pivotal Phase 3 Alzheimer’s Trial

Arch Biopartners Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase II Trial for LSALT Peptide

Ads